18F-mFBG PET Imaging in the Evaluation of Neuroblastoma

Sponsor
First Affiliated Hospital of Zhejiang University
Study ID
NCT06852807
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • 18F-MFBG — DRUG
    Patients with neuroblastoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.

Study Details

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.

Key Dates

First listed
Feb 28, 2025
Start date
Feb 4, 2025
Status verified
Jan 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2029

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: 18F-MFBG PET/CT in Neuroblastoma
    Each patient receive a single intravenous injection of 18F-MFBG 2-5 MBq/kg and undergo PET/CT or PET/MR scan after 60 min post-injection.

Primary Outcome Measure

Diagnostic efficacy [ Time Frame: through study completion, an average of 1.5 year ]

Central Contacts

Find similar trials

Nationwide
Neuroblastoma trialsOncology trialsPediatric oncology trials

Related Studies